Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine

Kevin R. Porter*, Daniel Ewing, Lan Chen, Shuenn Jue Wu, Curtis G. Hayes, Marilyn Ferrari, Nimfa Teneza-Mora, Kanakatte Raviprakash

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


A prototype dengue-1 DNA vaccine was shown to be safe and immunogenic in a previous Phase 1 clinical trial. Anti-dengue-1 neutralizing antibody responses were detectable only in the group of volunteers receiving the high dose of nonadjuvanted vaccine and the antibody titers were low. Vaxfectin ®, a lipid-based adjuvant, enhances the immunogenicity of DNA vaccines. We conducted a nonhuman primate study to evaluate the effect of Vaxfectin ® on the immunogenicity of a tetravalent dengue DNA vaccine. Animals were immunized on days 0, 28 and 84, with each immunization consisting of 3mg of Vaxfectin ®-adjuvanted tetravalent dengue DNA vaccine. The use of Vaxfectin ® resulted in a significant increase in anti-dengue neutralizing antibody responses against dengue-1, -3 and -4. There was little to no effect on T cell responses as measured by interferon gamma ELISPOT assay. Animals immunized with the Vaxfectin ®-formulated tetravalent DNA vaccine showed significant protection against live dengue-2 virus challenge compared to control animals (0.75 mean days of viremia vs 3.3 days). Animals vaccinated with nonadjuvanted DNA had a mean 2.0 days of viremia. These results support further evaluation of the Vaxfectin ®-adjuvanted tetravalent dengue DNA vaccine in a Phase 1 clinical trial.

Original languageEnglish
Pages (from-to)336-341
Number of pages6
Issue number2
StatePublished - 5 Jan 2012
Externally publishedYes


  • DNA vaccine
  • Dengue
  • Vaxfectin


Dive into the research topics of 'Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine'. Together they form a unique fingerprint.

Cite this